Source comparison
CJC-1295 No DAC & Ipamorelin Orally vs Subcutaneously: Administration Route Comparison
Bioavailability 95% (direct delivery to systemic circulation bypassing GI tract) Oral route results in near-zero therapeutic effect. 100× difference in plasma exposure Onset of GH Releas
This comparison does not assign a generated winner or score.
- Bioavailability
- <1% (degraded by gastric acid and digestive proteases before absorption)
- >95% (direct delivery to systemic circulation bypassing GI tract)
- Oral route results in near-zero therapeutic effect. 100× difference in plasma exposure
- Onset of GH Release
- None measurable (intact peptide never reaches GH-releasing receptors)
- 15–30 minutes post-injection (peak GH levels at 30–60 minutes)
- Subcutaneous injection produces measurable GH pulse; oral ingestion does not
- Peptide Stability
- Destroyed within 15–30 minutes by pepsin (pH 1.5–3.5) and pancreatic proteases
- Stable in reconstituted form for 28 days at 2–8°C; no enzymatic degradation pre-injection
- Oral delivery dismantles molecular structure before any receptor interaction occurs
- Dosing Frequency
- Not applicable (no effective dose exists for oral route)
- Once daily or every other day (CJC-1295 half-life: 6–8 days; Ipamorelin half-life: 2 hours)
- Subcutaneous dosing sustains therapeutic plasma levels; oral dosing provides zero sustained effect
- Cost Per Effective Dose
- Infinite (no amount of oral peptide produces measurable outcome)
- Approximately $3–8 per injection at research dosing (100–300 mcg CJC-1295, 200–300 mcg Ipamorelin)
- Attempting oral administration wastes 100% of compound cost with zero return
- Professional Assessment
- Pharmacologically ineffective. Peptide bond hydrolysis prevents systemic absorption entirely
- Only validated delivery method for CJC-1295 and Ipamorelin. Direct subcutaneous access achieves intended receptor activation and GH release
- Oral route is not a lower-convenience alternative; it is a complete failure mode. Subcutaneous injection is the baseline requirement for any peptide research application.